Structural alterations of the Wilms' tumor locus (WT1) at 11p13 have been implicated in the etiology of two human cancers ± Wilms' tumor (WT), a pediatric renal malignancy, and Desmoplastic Small Round Cell Tumor (DSRCT), an aggressive cancer of the abdomenal serosal lining with predilection for male adolescents. Germline mutations within the WT1 tumor suppressor gene predispose to WT and are associated with congenital malformations of the urogenital system, and somatic mutations are associated with initiation of transformation in WTs. In DSRCT, a recurrent translocation, t(11;22)(p13;q12), fuses the amino terminal domain of the EWS1 gene product to three of the four WT1 zinc ®ngers. Two EWS/WT1 isoforms are generated as a result of an alternative splicing event between zinc ®ngers III and IV, inserting or removing three amino acids (+KTS). We demonstrate that introduction of EWS/ WT1(7KTS) into NIH3T3 cells causes their tumorigenic transformation as determined by: formation of transformed foci on a monolayer of cells; anchorageindependent growth; and tumor formation in nude mice. EWS/WT1(+KTS) showed no transforming potential in these assays. These results indicate the oncogenic eect of the t(11;22) translocation is mediated by the EWS/ WT1(7KTS) isoform and that fusion of the EWS amino terminal domain to the WT1 DNA binding domain produces a chimeric product showing a gain of function.
Introduction
Structural alteration or aberrant expression of transcription factors is often a critical event in neoplastic transformation and has been described for many human cancers including primitive sarcomas of children and young adults such as Ewing sarcoma (EWS), primitive ectodermal tumor, and alveolar rhabdomyosarcoma (for review, see Ladanyi, 1995) . Characterization of translocation breakpoints in these cancers has frequently revealed fusion products between transcription factor eector domains and nucleic acid-binding domains, resulting in the generation of a potent oncogene with novel biological properties.
Desmoplastic Small Round Cell Tumor (DSRCT) is an aggressive, rare tumor that generally occurs in adolescent males and is located to the peritoneal surfaces of the abdomen. This malignancy is associated with a recurrent translocation t(11;22)(p13;q12), which fuses the N-terminal domain (NTD) of the EWS1 gene in frame to three of the four C-terminal zinc ®ngers of the WT1 tumor suppressor gene (Gerald et al., 1995; Ladanyi and Gerald, 1994) . The EWS/ WT1 chimeric product has novel functional properties. Unlike the WT1 tumor suppressor gene, which generally acts as a transcriptional repressor, EWS/ WT1 is a potent transcriptional activator (Karnieli et al., 1996; Rauscher et al., 1994) . EWS/WT1 recognizes the same DNA binding sites as WT1 and has been shown to activate transcription of the insulin-like growth factor-1 receptor gene (Karnieli et al., 1996; Rauscher et al., 1994) , a gene whose expression can be repressed by WT1 (Werner et al., 1994 (Werner et al., , 1995 . Although the transforming potential of EWS/WT1 has never been demonstrated, deregulation of WT1 downstream targets by EWS/WT1 is thought to play a role in tumorigenesis of DSRCT.
The EWS1 gene is involved in several tumor-related chromosomal translocations that produce fusions with genes postulated to function as transcription factors (for a review, see Ladanyi, 1995) . In each case, the translocation produces chimeric molecules containing the NTD of EWS1 (EWS-NTD) fused to the DNA binding domain of the partner. The EWS1 gene encodes a 656 amino acid protein that contains three arginine-and glycine-rich tracts and an 85 amino acid RNA recognition motif at its C-terminus. The EWS-NTD (aa 1 ± 285) is composed almost exclusively (*90%) of tyrosine, glutamine, glycine, alanine, serine, threonine, and proline residues organized in a repeated and degenerated polypeptide motif having the consensus, NSYGQQS. This domain shares distant homology to the C-terminal region of eukaryotic RNA polymerase II.
The Wilms' tumor gene, WT1, encodes a zinc-®nger transcription factor belonging to the EGR (early growth response) family of Cys 2 -His 2 zinc ®nger proteins and is mutated in 5 ± 15% of sporadic WTs (for a review, see Reddy and Licht, 1996) . Germline mutations in the WT1 gene are associated with abnormal urogenital system development observed in Denys-Drash and WAGR (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation) syndromes (Pelletier et al., 1991a,b) . The pre-mRNA is alternatively spliced at two coding exons to produce four WT1 polypeptide isoforms containing four zinc ®ngers (Reddy and Licht, 1996) . The second alternative splice site inserts (+) or removes (7) three amino acids, (+) lysine, threonine, and serine, between zinc ®ngers III and IV and alters the DNA binding speci®city of the protein (Rauscher et al., 1990) . This alternative splicing event is also functional in DSRCT and produces two EWS/WT1 isoforms with distinct DNA properties (Gerald et al., 1995; Rauscher et al., 1994) .
In this report, we demonstrate that EWS/ WT1(7KTS) is a dominantly acting oncogene, as measured by a number of criteria: cell growth kinetics, formation of transformed foci, anchorageindependent growth, and tumor formation in nude mice. The EWS/WT1(+KTS) isoform did not show transforming potential, suggesting that the oncogeneic eect of the t(11;22) translocation is solely due to EWS/WT1(7KTS S-methionine labeled cell extracts were immunoprecipitated with an antibody against the C-terminal region of WT1 zinc ®nger IV (C19; Santa Cruz) and analysed by SDS ± PAGE on a 10% polyacrylamide gel. Migration of prestained molecular weight markers (New England Biolabs) is indicated to the left (kDa)
Results

Establishment and characterization of cell lines expressing EWS/WT1 isoforms
Although the ews/wt1 gene has been shown to encode a transcriptional activator thought to contribute to tumorigenesis by deregulating expression of WT1-responsive genes, the transforming potential of either EWS/WT1 isoforms has never been reported. Given the presence of the EWS/WT1 fusion in DSCRTs, we felt this was an important issue to address, if one further wished to characterize activity of this protein product in a biological setting. To determine if overexpression of EWS/WT1 could alter cell growth kinetics, we infected NIH3T3 cells with a retroviral expression construct (Miller and Rosman, 1989) , pLXSN, containing the entire EWS/WT1 coding region (Figure 1a ). At the WT1 locus, an alternative splicing event between zinc ®ngers III and IV produces isoforms containing (+) or lacking (7) the three amino acids lysine, threonine, and serine (KTS). These isoforms localize to separate, but overlapping regions in the nucleus, suggesting possible functional differences (Larsson et al., 1995) . Since this alternative splicing event is maintained in the EWS/WT1 fusion products present in DSRCT (Gerald et al. 1995) , both EWS/WT1 isoforms were inserted into pLXSN. A pLXSN expression vector lacking EWS/WT1 cDNA sequences was used as a negative control. Following infection of NIH3T3 cells, 45 neomycin (G418)-resistant colonies were isolated and characterized. A detailed study of (a) the mass population ( The amount of EWS/WT1 protein in dierent clones was determined by immunoprecipitation analysis (Figure 1b ). Whereas no EWS/WT1 protein could be detected in NIH3T3 cells infected with pLXSN ( Figure  1b , lanes 1, 4, 7 and 10), the EWS/WT1(+KTS) isoforms were expressed at similar levels in all clonallyderived cell lines used in this study (Figure 1b) . Although the protein migrates as a *50 ± 55 kDa polypeptide, the predicted molecular mass of EWS/ WT1 is *40 kDa. This phenomenon has also been observed with EWS/WT1 protein produced from in vitro translations in rabbit reticulocyte lysate (JK and JP, data not shown) and may be due to the presence of the 31 proline residues within the NTD of EWS. The same phenomenon has been noticed with EWS/ATF1 fusions, which demonstrate an apparent molecular mass greater than predicted (Brown et al., 1995) .
EWS/WT1(7KTS), but not EWS/WT1(+KTS), transforms NIH3T3 cells
The growth properties of cell lines overexpressing the EWS/WT1(7KTS) isoform were markedly dierent from those expressing EWS/WT1(+KTS), or from those infected with the empty pLXSN expression vector. The doubling time of two dierent cell lines [(C1 and C2)] expressing EWS/WT1(7KTS) was reduced from 22.6 ± 26.2 h in NIH3T3 cells to 17.5 ± 18.1 h (Figure 2a , Table 1 ). Expression of EWS/ WT1(+KTS) did not signi®cantly alter the cell growth, relative to the pLXSN-infected NIH3T3 control cells. Cells overexpressing EWS/WT1(7KTS) also grew to a higher saturation density (2.5-fold) relative to NIH3T3 or EWS/WT1(+KTS) cells (Table  1) . Cells expressing EWS/WT1(7KTS) also showed changes in morphology, demonstrating increased refractility relative to NIH3T3 controls or cells expressing EWS/WT1(+KTS) (Figure 2b) . These results indicate a faster growth rate and a reduction in contact inhibition for cells expressing EWS/ WT1(7KTS) (Figure 2a , Table 1 ), suggesting a functional dierence between the EWS/WT1 isoforms.
Most transformed cells have apparently lost some of the hormone and growth factor requirements of normal cells, and are thus able to grow in initial Figure 2 Growth parameters of control cell lines and cell lines expressing EWS/WT1(+KTS) isoforms. (a) Growth curves of cell lines used in this study. Cells were seeded at 1610 5 cells per 60 mm dish and grown in Dulbecco's modi®ed essential medium (DMEM) supplemented with 10% fetal calf serum (FCS), 2 mM glutamine, 100 U ml 71 penicillin and 100 mg ml 71 streptomycin, in a 378C, 5% humidi®ed environment. Cells were counted at 2 day intervals with a hemacytometer for a total of 12 days. All results are the average of two experiments. (b) Morphological transformation of NIH3T3 cells Photograph of G418-selected cultures of NIH3T3 cells infected with pLXSN vector, pLXSN-EWS/WT1(+KTS), pLXSN-EWS/WT1(7KTS) DNAs. 633 magni®cation serum concentrations that are much lower than those required by normal cells. To investigate the serum dependency of cells expressing EWS/WT1 isoforms, clonally-derived lines were maintained for 2 weeks in 1 or 2% fetal calf serum. Following staining with hematoxyline, it became apparent that only cells expressing EWS/WT1(7KTS) showed signi®cant enhanced proliferation in low serum (Figure 3a) . These results attest to the reduced requirement on supplemental growth factors for EWS/WT1(7KTS) expressing cells.
Additional phenotypic changes associated with malignantly transformed cells are loss of capacity for growth arrest and anchorage-independent growth potential. When EWS/WT1(7KTS) expressing cell lines were grown to con¯uency, transformed foci formed on the cell monolayers (Figure 3b ). Cells expressing EWS/WT1(7KTS) had also lost their anchorage dependency since they showed the ability to grow in soft agar. Figure 3b shows macroscopic colonies (0.4 ± 1 mm in diameter) formed with EWS/ WT1(7KTS)(C1). Similar sized colonies were observed with other monoclonal cell lines expressing EWS/ WT1(7KTS), but not with control, or pLXSN-EWS/ WT1(+KTS)-expressing NIH3T3 cells (Figure 3b , Table 1 ). In addition, mass populations of pLXSN-EWS/WT1(7KTS)-infected cells, but not control or pLXSN-EWS/WT1(+KTS)-infected cells, were capable of focus formation (915+93 per 10 5 cells) and anchorage-independent growth (Table 1) indicating that the observed growth properties of the EWS/ WT1(7KTS) cell lines were not speci®c to these clonal derivatives. The eciency of colony formation in soft agar was 8.5 ± 13.9% (Table 1) , similar to the eciency of colony formation of cell lines transformed with other oncogenes (Amrein and Sefton, 1988) .
NIH3T3 cells expressing EWS/WT1 show increased tumorigenic growth potential
The above experiments suggest that EWS/ WT1(7KTS) is capable of transforming NIH3T3 cells in vitro. However, the most reliable determinant of tumorigenic transformation of NIH3T3 cells is the ability to form tumors when injected in nude mice. When cells (10 5 ) expressing EWS/WT1(7KTS) were injected into nude mice, tumors developed within a relatively short latent period (10 ± 14 days; Table 1 ). Tumors showed unlimited growth, and were characterized upon dissection as malignant ®brosarcomas (S Jothy, data not shown). Tumors were never found in nude mice injected with NIH3T3 cells or expressing EWS/WT1(+KTS) ( Table 1) .
Discussion
The tumorigenic potential of the EWS/WT1(7KTS) gene product is consistent with the idea that this chimeric protein plays a crucial role in DSRCT oncogenesis. The ecient and rapid growth of NIH3T3 cells expressing this protein in soft agar and in nude mice suggests that, in these contexts, EWS/WT1(7KTS) is a potent single-step transforming agent and that this system can be exploited to de®ne structure/function relationships of EWS/ WT1(7KTS). The EWS1 gene is found translocated in a wide variety of human solid tumors. The normal EWS1 gene encodes a widely expressed 656-amino acid protein composed of an NTD homologous to eukaryotic polymerase II and a carboxyl-terminal region with homology to RNA-binding domains (Figure 1a) . The NTD of EWS1 is juxtapositioned adjacent to the ETS-related DNA binding domain of FLI1, ERG, or ETV1 in Ewing's sarcoma and related primitive neuroectodermal family of tumors (Delattre et al., 1992; Jeon et al., 1995; Sorensen et al., 1994) ; and to the bZIP protein dimerization and DNA binding domain of ATF-1 in malignant melanoma of soft tissue (Zucman et al., 1993) . The EWS/FLI1 and EWS/ERG fusion are also capable of transforming NIH3T3 cells (May et al., 1993a,b; Ouchida et al., 1995) , and this activity, in the case of EWS/FLI1, has been shown to be dependent on the presence of an intact NTD and DNA binding domain (May et al., 1993b) . Doubling time and saturation densities were measured as described in the text. Results are the average of two experiments. Plating eciency and growth in soft agar are the results of at least three experiments. Cloning eciency in agar was calculated by the number of colonies6100 divided by the number of cells plated. Colonies were scored are cell aggregates containing more than 10 cells. In the soft agar assay, polyclonal cell populations of pLXSN infected NIH3T3 cells did not produce any colonies (JK and JP, data not shown). Mice that did not develop tumors were observed for 70 days. Latency (days) was determined as the number of days for tumors to reach 1.0 cm. C1, C2, C3, and C4 refer to monoclonal cell lines isolated from the polyclonal populations (P). n.d., not done Disruption of WT1 in susceptible target cells leads to tumorigenesis, consistent with its characterization as a tumor suppressor gene (reviewed in Reddy and Licht, 1996) . Re-introduction of wild-type WT1 into transformed cell lines suppresses cell growth, an eect observed with each of four naturally occurring splice variants McMaster et al., 1995) . Our results demonstrating an oncogenic function for EWS/ WT1(7KTS) indicates that the translocation event in DSRCT generates a chimeric molecule with a gain-offunction mutation. In addition, we have documented a clear functional dierence in transforming potential between the EWS/WT1(7KTS) and EWS/ WT1(+KTS) isoforms. Alternative splicing of the KTS amimo acids between WT1 zinc ®ngers III and IV, produces isoforms with very dierent DNA binding speci®city and anity Rauscher et al., 1994) (10 3 ) from each of the indicated clones were seeded onto 60 mm culture dishes in 0.3% (wt/vol) agar solution containing DMEM supplemented with 10% fetab bovine serum and 500 mg/ml of G418 (active concentration) (GIBCO BRL). After cooling to room temperature, cells were cultured at 378C in a humidi®ed, 5% CO 2 incubator. Colonies were scored after 16 days after plating633 magni®cation of colonies in soft agar et al., 1995) . The ratio of WT1(7KTS) to WT1(+KTS) isoforms is critical for normal WT1 function, since germline mutations within intron 9 which skew the ratio of spliced products towards the 7KTS isoforms, dramatically impairs urogenital system development and predisposes to WT (Bruening et al., 1992) . From our results, it is clear that only the EWS/WT1(7KTS) is necessary for transformation ([at least in NIH3T3 cells] ) and that EWS/WT1(+KTS) may not be necessary for DSCRT initiation or progression.
The mechanism by which EWS/WT1(7KTS) transforms cells is not clear. The deregulation of genes normally under control of WT1 is one possibility since loss of zinc ®nger I in the EWS/ WT1 fusion increases its anity for WT1 recognition sequences (JK, KL and JP, submitted) . Additionally, since WT1 zinc ®ngers II, III, and IV most closely resemble the three ®ngers of EGR (early growth response)-1 proteins, normal target genes for EGRs (or other zinc ®nger proteins) may also be deregulated by EWS/WT1(7KTS). Interestingly, a missense mutation within the WT1 gene that converts it into an activator of transcription has been described in a mesothelioma cell line , underscoring the relevance between deregulation of downstream WT1 targets and tumorigenesis.
The ®nding that EWS/WT1(7KTS) is an oncogene suggests that it is necessary for oncogenesis in DSRCT, and provides a unique paradigm for a means by which dierent alterations of transcription factor function can lead to diverse oncogenic processes. In DSRCT, additional genes may cooperate with EWS/WT1 or be required for tumor progression, and these remain to be identi®ed. DSRCTs are aggressive neoplasms, with an average survival of about 22 months (Gerald et al., 1991) . Elucidating the mechanism by which a gain-offunction mutation transforms cells will contribute signi®cantly to our understanding of control during normal and abnormal cell growth. Targeting EWS/ WT1(7KTS) domains (e.g. with small molecule inhibitors or by antisense inhibition) essential for transformation may lead to the development of novel therapeutic strategies for this aggressive disease.
Materials and methods
Retroviral infection
Full-length EWS/WT1(+KTS) or EWS/WT1(7KTS) cDNAs were subcloned into the EcoRI/XhoI sites of pLXSN. To generate recombinant retroviruses, the packaging mutant helper cell line C-2 (Mann et al., 1983) was transfected with 20 mg of pLXSN, pLXSN-EWS/ WT1(+KTS), or pLXSN-EWS/WT1(7KTS) plasmids. Transfectants were selected in medium containing 500 mg ml 71 G418 (neomycin). The virus was collected and used to infect NIH3T3 cells in 100 mm dishes, as described (Krauss et al., 1992) . After dilution of the polyclonal cell lines, monoclonal cell lines were isolated by picking individual G418-resistant colonies.
Immunoprecipitation of EWS/WT1 protein
Monoclonal NIH3T3 cell lines were metabolically labeled with 35 S-methionine (100 mCi/ml) in methionine-free DMEM supplemented with 10% dialyzed fetal calf serum for 4 h, at which point the media was supplemented with fresh DMEM (10% fetal calf serum, v/v) and cells were incubated for another 12 h. Cell extracts were prepared by sonication in RIPA buer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1.0% Nonidet P40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate). Following removal of debris by centrifugation (612 000 g/10 min), cell extracts were pre-cleared twice with pre-immune serum and Protein A Sepharose conjugate. Immunoprecipitations were performed with anti-WT1 C19 antibody (Santa Cruz) conjugated to Protein A, analysed by 10% SDS ± PAGE, and visualized by¯uorography.
Characterization of growth rate, saturation density and serum dependency
Equal numbers of cells (1610 5 ) from individual clones were seeded onto 60 mm dishes and incubated at 378C. At 2-day intervals for 12 days the viable cells were counted in duplicate for each point by trypan blue exclusion using a hemacytometer. The growth rates and saturation densities were determined from the slope of the logarithmic curve during exponential growth and cell densities that developed during the plateau phase of growth, respectively. Serum dependency was also determined by comparing the growth rates of the cells maintained in DMEM supplemented with 1% or 2% fetal bovine serum. Each cell line was plated at a density of 10 3 cells in 60 mm dishes and allowed to attach for 24 h in growth medium (DMEM) supplemented with 10% (v/v) fetal bovine serum. Media in the dishes was then changed to DMEM supplemented with 1 or 2% (v/v) fetal bovine serum. The dishes were maintained in the designated serum concentration for 2 weeks, with the addition of fresh media every 2 days, then ®xed in 2.5% glutaraldehyde (in PBS) and stained with hematoxylin (Sigma).
Tumorigenic assays in nude mice
Tumorigenic assays were performed in nude mice as previously described (Bookstein et al., 1990) . In brief, 10 5 cells from each clone in 100 ml PBS were injected subcutaneously into the left side near the lower limb of 4 ± 8-week old athymic nude mice (CD1 nu/nu; Charles River). Mice that developed tumors were killed after 16 days, at which time the average diameter of the tumor was *2.0 cm. Mice that did not develop tumors were observed for 70 days.
